Complementary roles of gasotransmitters CO and H2S in sleep apnea.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28115703.
- Also identified by DOI 10.1073/pnas.1620717114 and PMC identifier 5307452.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sleep apnea, which is the periodic cessation of breathing during sleep, is a major health problem affecting over 10 million people in the United States and is associated with several sequelae, including hypertension and stroke. Clinical studies suggest that abnormal carotid body (CB) activity may be a driver of sleep apnea. Because gaseous molecules are important determinants of CB activity, aberrations in their signaling could lead to sleep apnea. Here, we report that mice deficient in heme oxygenase-2 (HO-2), which generates the gaseous molecule carbon monoxide (CO), exhibit sleep apnea characterized by high apnea and hypopnea indices during rapid eye movement (REM) sleep. Similar high apnea and hypopnea indices were also noted in prehypertensive spontaneously hypertensive (SH) rats, which are known to exhibit CB hyperactivity. We identified the gaseous molecule hydrogen sulfide (H<sub>2</sub>S) as the major effector molecule driving apneas. Genetic ablation of the H<sub>2</sub>S-synthesizing enzyme cystathionine-γ-lyase (CSE) normalized breathing in HO-2<sup>-/-</sup> mice. Pharmacologic inhibition of CSE with l-propargyl glycine prevented apneas in both HO-2<sup>-/-</sup> mice and SH rats. These observations demonstrate that dysregulated CO and H<sub>2</sub>S signaling in the CB leads to apneas and suggest that CSE inhibition may be a useful therapeutic intervention for preventing CB-driven sleep apnea.
Medical subject headings
- Carbon Monoxide
- Gasotransmitters
- Hydrogen Sulfide
- Sleep Apnea Syndromes